A CT imaging hydrogel, its preparation method and application
By cross-linking multi-arm polyethylene glycol and iodinated polyaldehyde compounds capped with succinimide esters with polyamino compounds, a CT-developable hydrogel is formed, which solves the problems of insufficient MRI development and insufficient stability of existing hydrogels during radiotherapy, achieves the effects of rapid gelation and long-term development, and is suitable for radiotherapy protective gaskets.
Patent Information
- Application Number
- CN202310820685.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-05
- Publication Date
- 2025-09-09
- Estimated Expiration
- 2043-07-05
AI Technical Summary
Existing hydrogel materials only have MRI imaging function during radiotherapy, which cannot meet the diagnostic needs of some patients with metal implants in their bodies. At the same time, MRI diagnosis is expensive and time-consuming, and most hydrogels are not stable enough in the body to meet the needs of long-term radiotherapy cycles.
Multi-arm polyethylene glycol terminated with succinimide ester and iodinated polyaldehyde compounds are cross-linked with polyamino compounds to form a hydrogel with CT imaging function. A stable network structure is generated through the cross-linking reaction to ensure long-term stability in vivo and in vitro.
The hydrogel can quickly gel within 2 seconds and maintain its imaging function for 1.5 to 3 months both in vitro and in vivo, meeting the needs of long-term radiotherapy cycles, avoiding the high cost and long diagnosis of MRI, and is suitable for radiotherapy protective gaskets.
Smart Images

Figure CN116688163B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a CT developing hydrogel, a preparation method and an application thereof. Background Art
[0002] Radiotherapy is a common treatment for cancer, but it may cause unintended radiation damage to adjacent healthy tissues, which can affect patients' health and quality of life. In recent years, radiation oncologists have considered using "spacing" techniques, such as placing radiotherapy spacers to separate tumor tissue and normal tissue, to reduce the risk of radiation damage to surrounding tissues during radiotherapy.
[0003] Hydrogels are soft materials containing large amounts of water, formed by precursor reactions of biocompatible cross-linked polymers with electrophilic and nucleophilic groups. They possess excellent physical and chemical properties and biological characteristics, and have significant applications in biomedical research fields such as drug transport and tissue engineering. They are ideal materials for tumor radiotherapy spacers. Injectable hydrogels, a type of hydrogel that exhibits a certain degree of fluidity and can be applied by injection, are liquid or semisolid with shear-thinning properties before injection into the human body. After injection, they gel in situ, eliminating the need for invasive surgery, effectively avoiding the risk of infection, and reducing patient pain. Currently, polyethylene glycol (PEG) hydrogels are widely used due to their excellent biocompatibility. Various injectable PEG hydrogels have been developed, including amphiphilic polyester / polypeptide hydrogels with PEG as the hydrophilic segment, PEG hydrogels prepared by supramolecular interactions, and PEG hydrogels prepared through mild chemical reactions.
[0004] Hydrogels are currently being used clinically as ideal materials for tumor radiotherapy spacers, achieving excellent clinical results. However, most hydrogels only offer MRI imaging capabilities, making MRI diagnostics and preoperative localization difficult for some patients with metal implants. Furthermore, MRI is expensive and time-consuming. Therefore, the development of hydrogels with additional imaging capabilities is urgently needed.
[0005] Furthermore, radiotherapy treatment cycles are long, typically exceeding a month. Therefore, hydrogels used for radiotherapy protection must maintain stability in the body for extended periods. Furthermore, the hydrogel's raw material solution must gel quickly after injection to prevent the solution from seeping into other parts of the body. Summary of the Invention
[0006] In view of this, the present invention aims to provide a CT imaging hydrogel, a preparation method, and applications thereof. The CT imaging hydrogel solution can rapidly gel after injection into the body, and the formed hydrogel maintains excellent imaging function even after three months in the body.
[0007] To achieve this object, the present invention adopts the following technical solutions:
[0008] In a first aspect, the present invention provides a CT imaging hydrogel, which is obtained by in situ cross-linking a hydrogel base material and a cross-linking agent;
[0009] The hydrogel base material includes succinimide ester-terminated multi-arm polyethylene glycol and an iodinated multialdehyde compound;
[0010] The iodinated polyaldehyde compound is an aldehyde compound obtained by oxidizing an iodine-containing contrast agent;
[0011] The cross-linking agent is a polyamino compound.
[0012] Preferably, the iodine-containing contrast agent is any one or more of iopromide, iopamidol, diatrizoate, iohexol or iodixanol.
[0013] Preferably, the iodinated polyaldehyde compound is iodine hexaldehyde.
[0014] Preferably, the molar ratio of the amino group in the polyamino compound, the succinimide ester-terminated multi-arm polyethylene glycol, and the aldehyde group in the iodinated polyaldehyde compound is (0.3-30):(0.1-10):1.
[0015] Preferably, the polyamino compound is any one or more of trilysine, pentalysine, ε-polylysine, α-polylysine, poly-L-lysine or polyethyleneimine.
[0016] Preferably, the number of arms of the succinimide ester-terminated multi-arm polyethylene glycol is selected from integers of 4 to 10, and the molecular weight is 5,000 to 20,000.
[0017] In a second aspect, the present invention provides a method for preparing the above-mentioned CT imaging hydrogel, comprising the following steps:
[0018] S1: mixing a succinimide ester-terminated multi-arm polyethylene glycol, an iodinated polyaldehyde compound, and a first buffer solution to obtain solution A; mixing a polyamino compound and a second buffer solution to obtain solution B;
[0019] S2: After mixing solution A and solution B, a CT imaging hydrogel is obtained.
[0020] Preferably, the first buffer solution is PBS buffer, and the second buffer solution is borate buffer.
[0021] Preferably, the pH of the solution A is 6-7.5, and the pH of the solution B is 7-10.
[0022] In a third aspect, the present invention provides a medical radiotherapy protective gasket, comprising the CT imaging hydrogel involved in the above technical solution.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] The present invention also provides a CT-developable hydrogel. The CT-developable hydrogel first reacts the activated ester in a succinimide-ester-capped multi-arm polyethylene glycol with the amino groups in a polyamino compound to form stable amide bonds. The aldehyde groups in the iodinated polyaldehyde compound then undergo a Schiff base reaction with the amino groups in the polyamino compound, which then undergoes a nucleophilic addition reaction with the amide bonds to produce crosslinks, resulting in a solid hydrogel with a stable network structure and elasticity. Research has shown that the hydrogel has a short gelation time, achieving gelation within 2 seconds. CT testing has also shown that the hydrogel can maintain its gel mass for 1.5 to 3 months in vitro and 1.5 to 3 months in vivo. This demonstrates that the hydrogel provided by the present invention can maintain long-term stability in vivo. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 This is a graph showing changes in the CT value of the hydrogel obtained in Example 1 over time in vivo;
[0026] Figure 2 This is a graph showing changes in the CT value of the hydrogel obtained in Example 2 over time in vivo;
[0027] Figure 3 This is a graph showing changes in the CT value of the hydrogel obtained in Example 3 over time in vivo;
[0028] Figure 4 This is a graph showing changes in the CT value of the hydrogel obtained in Example 4 over time in vivo;
[0029] Figure 5 This is a graph showing changes in the CT value of the hydrogel obtained in Example 5 over time in vivo;
[0030] Figure 6 This is a graph showing changes in the CT value of the hydrogel obtained in Example 6 over time in vivo;
[0031] Figure 7 This is a graph showing changes in the CT value of the hydrogel obtained in Example 7 over time in vivo;
[0032] Figure 8 This is a graph showing changes in the CT value of the hydrogel obtained in Example 8 over time in vivo;
[0033] Figure 9 This is a graph showing changes in the CT value of the hydrogel obtained in Example 9 over time in vivo;
[0034] Figure 10 This is a graph showing changes in the CT value of the hydrogel obtained in Example 10 over time in vivo;
[0035] Figure 11 1 is a graph showing changes in CT value of the hydrogel obtained in Example 11 over time in vivo;
[0036] Figure 12 This is a graph showing the changes in CT value of the hydrogel obtained in Comparative Example 1 over time in vivo. DETAILED DESCRIPTION
[0037] The following will clearly and completely describe the technical solutions of the present invention in conjunction with the embodiments of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.
[0038] In response to the problem that hydrogels in the prior art only have MRI development functions, the present invention provides a CT development hydrogel, which is obtained by in situ cross-linking of a hydrogel base and a cross-linking agent. In the present invention, the hydrogel base comprises multi-arm polyethylene glycol and an iodinated multi-aldehyde compound. Among them, the end groups of the multi-arm polyethylene glycol can be functional groups such as succinimidyl glutarate, aldehyde, thiol, imine, Schiff base, etc., and the multi-arm polyethylene glycol is preferably a polyethylene glycol terminated with succinimidyl glutarate, aldehyde, and thiol, and more preferably a multi-arm polyethylene glycol terminated with succinimidyl glutarate (hereinafter also referred to as "succinimidyl ester terminated multi-arm polyethylene glycol"). The structural formula of the succinimidyl glutarate terminated multi-arm polyethylene glycol is as follows:
[0039]
[0040] Wherein, a is a positive integer from 2 to 10, and can be 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0041] The iodinated polyaldehyde compound is an aldehyde compound obtained after oxidation of an iodine-containing contrast agent. The present invention has no particular restrictions on the treatment mode of oxidation, and can be carried out according to technical means well known to those skilled in the art, such as metal oxides (potassium chromate, chromic acid, etc.), manganese dioxide, trichloroisocyanuric acid, hydrogen peroxide, sodium periodate oxidation or other oxidant oxidation. In the present invention, the iodine-containing contrast agent can be selected from any one or more of iopromide, iopamidol, diatrizoate, iohexol or iodixanol, preferably iohexol. The aldehyde compound obtained after oxidation of the iohexol is iodine aldehyde, so in the present invention, it is preferred that the iodinated polyaldehyde compound is iodine aldehyde. The present invention has no particular restrictions on the source of the multi-arm polyethylene glycol and the iodine-containing contrast agent capped with the succinimide ester, and can be a general commercial product. In some embodiments of the present invention, the number of arms of the succinimide ester-terminated multi-arm polyethylene glycol is selected from an integer of 4 to 10, which can be 4, 5, 6, 7, 8, 9 or 10; the molecular weight is 5000 to 20000, which can be 5000, 8000, 10000, 12000, 15000, 18000 or 20000, etc.
[0042] In the present invention, the cross-linking agent is a polyamino compound, which can be selected from any one or more of trilysine, pentalysine, ε-polylysine, α-polylysine, poly-L-lysine or polyethyleneimine, preferably any one or more of trilysine, ε-polylysine or poly-L-lysine, and most preferably trilysine and / or ε-polylysine.
[0043] In the present invention, the CT-developing hydrogel first reacts the activated ester in the succinimide-terminated multi-arm polyethylene glycol with the amino groups in the polyamino compound to form stable amide bonds. The aldehyde groups in the iodinated polyaldehyde compound then undergo a Schiff base reaction with the amino groups in the polyamino compound, and further undergo a nucleophilic addition reaction with the amide bonds to produce crosslinks, resulting in a solid hydrogel with a stable network structure and elasticity. Therefore, the multi-arm polyethylene glycol, iodinated polyaldehyde compound, and polyamino compound must be considered as a whole, and the ratio of the three must be within an appropriate range; otherwise, the crosslinking strength of the hydrogel will be adversely affected. In some embodiments of the present invention, the molar ratio of the amino group in the polyamino compound, the succinimide ester-terminated multi-arm polyethylene glycol and the aldehyde group in the iodinated polyaldehyde compound is (0.3-30): (0.1-10): 1, wherein the (0.3-30) can be 0.3, 0.5, 1, 3, 5, 8, 10, 13, 15, 18, 20, 23, 25, 28 or 30, etc., and the (0.1-10) can be 0.1, 0.5, 0.8, 1, 3, 5, 8 or 10, etc.
[0044] The existing commercial disposable absorbable isolation hydrogels that can be used clinically are mainly products of Poco and Sexes, which are 4-arm polyethylene glycol hydrogels formed by the reaction of 4-arm polyethylene glycol and a cross-linking agent. Among them, the 4-arm polyethylene glycol hydrogel is a hydrogel with a uniform network structure. Its structure gives it good force synergy and excellent mechanical properties, including tensile breaking strength, tensile breaking elongation, etc. At the same time, the 4-arm polyethylene glycol hydrogel also has biocompatibility, but it does not have CT imaging function and cannot be used for radiotherapy. In addition, the present invention has found through research that when a hydrogel is prepared directly using iodine-terminated polyethylene glycol, after it is placed in the body, the CT value decreases very quickly, and it is no longer obvious on the 7th day, and cannot fully cover the entire radiotherapy cycle of some patients. The CT value of the CT imaging hydrogel provided by the present invention can be maintained for 1.5 to 3 months in vitro and 1.5 to 3 months in vivo. It can be seen that the hydrogel provided by the present invention can maintain stability for a long time in vitro and in vivo. In the present invention, the CT value of the CT-developable hydrogel is 150-500 HU, preferably 200-500 HU, and more preferably 300-500 HU. Furthermore, the present invention has found that the amino group content in the polyamino compound (i.e., cross-linking agent) and the type of iodinated polyaldehyde compound (i.e., developer) significantly affect the degradation rate of the hydrogel. When the molar ratio of amino groups in the polyamino compound to aldehyde groups in polyethylene glycol and iodinated polyaldehyde compound is (0.5-1:1), such as 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, or 1:1, the hydrogel degradation rate is slow, and the CT value remains relatively significant after three months in vivo and in vitro.
[0045] The present invention also provides a method for preparing the above-mentioned CT imaging hydrogel, comprising the following steps:
[0046] S1: mixing a succinimide ester-terminated multi-arm polyethylene glycol, an iodinated polyaldehyde compound, and a first buffer solution to obtain solution A; mixing a polyamino compound and a second buffer solution to obtain solution B;
[0047] S2: After mixing solution A and solution B, a CT imaging hydrogel is obtained.
[0048] According to the present invention, a succinimide ester-terminated multi-arm polyethylene glycol and an iodinated polyaldehyde compound are first mixed with a first buffer solution to obtain solution A. The succinimide ester-terminated multi-arm polyethylene glycol and the iodinated polyaldehyde compound are as described in the above technical solution and are not repeated here. The first buffer solution is preferably PBS buffer, and the pH of the prepared solution A is 6 to 7.5, which can be 6, 6.2, 6.5, 6.7, 7.0, 7.2, 7.4 or 7.5, etc.
[0049] Then, the polyamino compound is mixed with a second buffer solution to obtain solution B. The polyamino compound is as described in the relevant content of the above technical solution and is not repeated here. The second buffer solution is preferably a borate buffer solution, and the pH of the resulting solution B is 7 to 10, which can be 7, 7.5, 8, 8.5, 9, 9.5, or 10, etc.
[0050] In the present invention, the point values listed above are merely for illustration purposes and are not limited thereto. Other point values within the numerical range are applicable and will not be described in detail here.
[0051] It should be noted that in the present invention, the first buffer solution serves as a powder diluent, and the second buffer solution serves to adjust the pH of the optimal reaction solution. The pH of Solution A and Solution B, when mixed, is within the aforementioned range to ensure a short gelling time and good stability. A pH that is too low will result in a prolonged reaction time, causing the solution to gel elsewhere. A high pH will result in a rapid reaction time, leading to premature gel formation and potentially blocking the puncture needle.
[0052] After obtaining solution A and solution B, the present invention preferably mixes solution A and solution B and then pumps them out to obtain a hydrogel. The volume ratio of solution A to solution B is preferably 1:(0.5-2), more preferably 1:(0.8-1.5), and most preferably 1:1.
[0053] In some embodiments of the present invention, succinimide ester-terminated multi-arm polyethylene glycol and iodinated polyaldehyde compounds are placed in a powder bottle, and then the powder diluent (i.e., the first buffer solution) is injected into the powder bottle. After the powder is dissolved, it is sucked out and mixed with solution B in proportion through a delivery system to form a hydrogel.
[0054] In some embodiments of the present invention, the succinimide ester-terminated multi-arm polyethylene glycol is preferably 8-arm polyethylene glycol succinimide glutarate (8-Arm PEG-SG), the structural formula of which is shown in Formula 1 or Formula 2 below:
[0055]
[0056] The 8-Arm PEG-SG has 8 activated esters, and the preferred iodinated polyaldehyde compound is iodine hexane (DHQ), which has 3 aldehyde groups, and the polyamino compound is polylysine. When in use, solution A and solution B are mixed through a delivery system and injected into the human body, where they react rapidly. The reaction principle is that the 8 activated esters of 8-arm polyethylene glycol succinimidyl glutarate (8-Arm PEG-SG) react with the amino groups of polylysine to form stable amide bonds, and the 3 aldehyde groups on iodine hexane (DHQ) react with the amino groups on polylysine to form Schiff bases, and also undergo nucleophilic addition reactions with the amide bonds to produce crosslinking. After the reaction is completed, solution A and solution B quickly change from liquids to elastic solid hydrogels.
[0057] In some embodiments of the present invention, after mixing Solution A and Solution B, the mixed solution is dispensed using a tubular tool (e.g., a syringe), forming a hydrogel in as little as 2 seconds. The hydrogel is then placed in a 37°C incubator to simulate the in vivo environment. CT scans are performed every 7 days to observe changes in CT values. Studies have found that under in vitro conditions, the hydrogel maintains a significant CT value for 1.5 to 3 months.
[0058] Furthermore, the present invention placed the hydrogel in animals and observed changes in CT values under a realistic in vivo environment. The results showed that the hydrogel maintained a significant CT value even after 1.5 to 3 months of placement. These results demonstrate that the hydrogel provided by the present invention has good stability both in vivo and in vitro, and its slow degradation rate allows for CT testing over a long period of time, meeting the needs of practical applications.
[0059] The preparation method of the CT imaging hydrogel provided by the present invention is simple and convenient, does not require expensive instruments and equipment, and is conducive to industrial or industrial production. Compared with the one-step mixing of succinimide ester-capped multi-arm polyethylene glycol, iodinated polyaldehyde compound and polyamino compound, the present invention mixes the prepared solution A and solution B and then pumps them out to form the hydrogel, which has the advantage of a short gelation time.
[0060] It should be noted that in other embodiments of the present invention, iodinated polyaldehyde compounds and polyamino compounds may not be added. Instead, an amino-containing iodine compound may be directly used as a crosslinker, and then crosslinked with multi-arm polyethylene glycol to form a hydrogel. For example, tri-lysine, penta-lysine, or poly-lysine may be grafted with an iodine-containing compound such as triiodoisophthalic acid as a crosslinker. The present invention does not specifically limit the number of iodine-containing compounds such as triiodoisophthalic acid grafted, and 1 to (n-1) grafts may be grafted, where n is the number of lysine residues.
[0061] The CT imaging hydrogel provided by the present invention has CT imaging function and maintains it in the body for a long time. Therefore, the present invention also provides a medical radiotherapy protective gasket for isolating normal tissue and diseased tissue in the body. The medical radiotherapy protective gasket includes the CT imaging hydrogel involved in the above technical solution.
[0062] In order to further illustrate the present invention, the following examples are provided for detailed description. The experimental raw materials used in the following examples of the present invention are all commonly available commercial products.
[0063] Preparation Example 1
[0064] Synthesis of 2,4,6-triiodo-N1,N3-bis(2-oxoethyl)-5-[N-(2-oxoethyl)acetylamino]benzene-1,3-dicarboxamide (iodine hexane, DHQ):
[0065] Dissolve 1 g of iohexol (5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide) powder in 1 mL of purified water, and dissolve 0.8 g of sodium periodate in 8 mL of purified water. Rapidly add the sodium periodate solution dropwise to the iohexol solution, mix under an ice bath, raise the temperature to 25°C, and react for 30 minutes. After the reaction is completed, treat with ethanol and centrifuge and dry to obtain white powder iohexal.
[0066] Example 1
[0067] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 128 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 55 mg of ε-polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups of DHQ was approximately 1.5:1:2) and pumped out. A hydrogel formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0068] The obtained hydrogel was scanned with CT every 7 days to observe the changes. It was found that the CT value decreased significantly after three months, but it could still reach about 100HU, indicating that the CT value of the gel block can be maintained for three months in vitro.
[0069] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 1 As shown, the CT value of the hydrogel was found to last for three months in rats.
[0070] Example 2
[0071] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 128 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 66 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups of DHQ was approximately 2:1:2) and pumped out. A hydrogel formed in about 2 s, and the hydrogel was placed in a 37°C incubator.
[0072] The obtained hydrogel was subjected to CT scanning every 7 days to observe the changes, and it was found that the CT value became significantly lower after three months, but the CT value was significant, indicating that the CT value of the gel block can be maintained for three months in vitro.
[0073] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 2 As shown, the CT value of the hydrogel was found to last for three months in rats.
[0074] Example 3
[0075] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 256 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 77.4 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups of DHQ was approximately 2:1:4) and pumped out. A hydrogel formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0076] The obtained hydrogel was subjected to CT scan every 7 days to observe the changes, and it was found that the CT value became lower after three months, but the CT value was obvious, and the CT value of the gel block could be maintained for three months in vitro.
[0077] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 3 As shown, it was found that the CT value of the hydrogel could last for at least three months in rats, and the CT value at three months was 275.24HU.
[0078] Example 4
[0079] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 128 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 81.52 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups of DHQ was approximately 2.5:1:2) and pumped out. A hydrogel formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0080] The obtained hydrogel was subjected to CT scan every 7 days to observe the changes, and it was found that the CT value became lower after 2.5 months, but the CT value was obvious, and the CT value of the gel block could be maintained for 2.5 months in vitro.
[0081] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 4 As shown, the CT value of the hydrogel was found to last for 2.5 months in rats.
[0082] Example 5
[0083] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 128 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 101.9 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups in DHQ was approximately 3:1:2) and pumped out to form a hydrogel in about 2 seconds. The hydrogel was placed in a 37°C incubator.
[0084] The obtained hydrogel was subjected to CT scan every 7 days to observe the changes, and it was found that the CT value became lower after 2.5 months, but the CT value was obvious, and the CT value of the gel block could be maintained for 2.5 months in vitro.
[0085] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 5 As shown, the CT value of the hydrogel was found to last for 2.5 months in rats.
[0086] Example 6
[0087] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 128 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 152.85 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups in DHQ was approximately 4.5:1:2) and pumped out to form a hydrogel in about 2 seconds. The hydrogel was placed in a 37°C incubator.
[0088] The obtained hydrogel was scanned with CT every 7 days to observe the changes. It was found that the CT value was basically 0 after 1.8 months, indicating that the CT value of the hydrogel can be maintained for 1.8 months in vitro.
[0089] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 6 As shown, the CT value of the hydrogel was found to last for 1.8 months in rats.
[0090] Example 7
[0091] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 128 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 203.8 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups in DHQ was approximately 6:1:2) and pumped out. A hydrogel was formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0092] The obtained hydrogel was scanned with CT every 7 days to observe the changes. It was found that the CT value was basically 0 after 1.8 months, indicating that the CT value of the hydrogel can be maintained for 1.8 months in vitro.
[0093] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 7 As shown, the CT value of the hydrogel was found to last for 1.8 months in rats.
[0094] Example 8
[0095] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 256 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 135.77 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups in DHQ was approximately 4:1:4) and pumped out. A hydrogel was formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0096] The obtained hydrogel was scanned with CT every 7 days to observe the changes. It was found that the CT value decreased after 2 months, but the value was significant, indicating that the CT value of the gel block can be maintained for 2 months in vitro.
[0097] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 8 As shown, the CT value of the hydrogel was found to last for 2.5 months in rats.
[0098] Example 9
[0099] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 256 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 169.7 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups in DHQ was approximately 5:1:4) and pumped out. A hydrogel was formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0100] The obtained hydrogel was scanned with CT every 7 days to observe the changes. It was found that the CT value was not obvious after 2 months, indicating that the CT value of the hydrogel can be maintained for 2 months in vitro.
[0101] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 9 As shown, the CT value of the hydrogel was found to last for 2 months in rats.
[0102] Example 10
[0103] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 256 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 254.5 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups in DHQ was approximately 7.5:1:4) and pumped out. A hydrogel formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0104] The obtained hydrogel was scanned with CT every 7 days to observe the changes. It was found that the CT value was not obvious after 2 months, indicating that the CT value of the hydrogel can be maintained for 2 months in vitro.
[0105] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 10 As shown, the CT value of the hydrogel was found to last for 2 months in rats.
[0106] Example 11
[0107] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 256 mg of DHQ were weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 321.4 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups, activated esters in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde groups in DHQ was approximately 10:1:4) and pumped out. A hydrogel was formed in about 2 seconds, and the hydrogel was placed in a 37°C incubator.
[0108] The obtained hydrogel was scanned with CT every 7 days to observe the changes. It was found that the CT value was basically 0 after 1.5 months, indicating that the CT value of the hydrogel can be maintained for 1.5 months in vitro.
[0109] The gel block was implanted in the body and CT scans were performed every 7 days. Figure 11 As shown, the CT value of the hydrogel was found to last for 1.5 months in rats.
[0110] Example 12
[0111] 492 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 7.5 mg of iodine hexane were dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 56 mg of trilysine was dissolved in 2.5 mL of borate buffer (pH = 13.1) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino group, activated ester in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde group of iodine hexane was approximately 2:1:0.1) and injected. It was found that the injection needle was blocked at 15 cm.
[0112] Example 13
[0113] 492 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 7.5 mg of iodine aldehyde were dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 56 mg of trilysine was dissolved in 2.5 mL of borate buffer (pH = 12.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino group, activated ester in eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde group of iodine aldehyde was approximately 2:1:0.1) and pumped out. A hydrogel was formed in about 20 seconds, and the hydrogel was placed in a 37°C incubator.
[0114] The obtained hydrogel was scanned with CT every 7 days to observe the changes, and it was found that the CT value had no signal after 7 days.
[0115] Example 14
[0116] 492 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K and 7.5 mg of iodine hexane were dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 56 mg of trilysine was dissolved in 2.5 mL of borate buffer (pH = 12) as solution B. Solutions A and B were mixed in equal volumes (the molar ratio of amino group, multi-arm polyethylene glycol activated ester terminated by succinimidyl ester, and aldehyde group was approximately 2:1:0.1) and pumped out. A hydrogel was formed in about 35 seconds, and the hydrogel was placed in a 37°C incubator.
[0117] The obtained hydrogel was scanned with CT every 7 days to observe the changes, and it was found that the CT value had no signal after 7 days.
[0118] Example 15
[0119] 492 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K was weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A, and 5 mg of trilysine and 84 mg of iodine hexane were weighed and dissolved in 2.5 mL of borate buffer (pH = 10) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino group, activated ester of eight-arm polyethylene glycol succinimidyl glutarate, and aldehyde group of iodine hexane was approximately 0.2:1:1.3) and pumped out to form a hydrogel in about 2 seconds. The hydrogel was placed in a 37°C incubator.
[0120] The obtained hydrogel was scanned with CT every 7 days to observe the changes, and it was found that the CT value had no signal at 14 days.
[0121] The CT test results of Examples 1 to 11 indicate that the hydrogels provided by the present invention maintain CT values for a long time, not less than 1.5 months, both in vitro and in vivo, demonstrating good stability and facilitating practical applications. The CT test results of Examples 12 to 15 indicate that when the dosage of the iodinated polyaldehyde compound is too low, the CT value of the hydrogels can be maintained for a shorter time.
[0122] Comparative Example 1
[0123] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K, which contains three end-capped grafted iodine compounds, was weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A. 16.7 mg of trilysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups to multi-arm polyethylene glycol activated esters capped with succinimidyl esters was 1:1) and pumped out. It took about 2 seconds to form a gel to obtain a hydrogel block.
[0124] The gel block was implanted into the body and CT scan was performed every day to observe the changes in CT values. The results were as follows: Figure 12 As shown in the figure, the CT value of the gel block dropped sharply from the 1st day to the 7th day. After 7 days, the CT value dropped to 13HU, which was difficult to detect.
[0125] Comparative Example 2
[0126] 500 mg of eight-arm polyethylene glycol succinimidyl glutarate (HG)-15K, three of which are end-capped with iodine, was weighed and dissolved in 2.3 mL of PBS buffer (pH = 7.4) as solution A. 21.36 mg of polylysine was weighed and dissolved in 2.5 mL of borate buffer (pH = 9.5) as solution B. Equal volumes of solutions A and B were mixed (the molar ratio of amino groups to multi-arm polyethylene glycol activated esters end-capped with succinimidyl esters was 1:1) and pumped out. It took about 2 seconds to form a gel to obtain a hydrogel block.
[0127] The gel block was implanted into the body and CT scan was performed every day to observe the changes in CT values. The results were as follows: Figure 12 As shown in the figure, the CT value of the gel block dropped sharply from the 1st day to the 7th day. After 7 days, the CT value dropped to 13HU, which was difficult to detect.
[0128] Unlike the examples in which iodinated polyaldehyde compounds were used as CT contrast agents, the hydrogel in Comparative Example 1 was prepared directly using iodine-terminated polyethylene glycol. CT test results showed that after being placed in the body, the CT value decreased very quickly and was no longer obvious on the 7th day, which is not conducive to practical application.
[0129] The above description of the disclosed embodiments will enable one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be readily apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention is not limited to the embodiments shown herein but is to be construed in the widest manner consistent with the principles and novel features disclosed herein.
Claims
1. A CT imaging hydrogel, characterized in that: It is obtained by in-situ cross-linking of a hydrogel base material and a cross-linking agent; The hydrogel base material includes succinimide ester-terminated multi-arm polyethylene glycol and an iodinated multialdehyde compound; The iodinated polyaldehyde compound is an aldehyde compound obtained by oxidizing an iodine-containing contrast agent; The cross-linking agent is polylysine; The molar ratio of the amino group in the polylysine, the activated ester in the succinimide ester-terminated multi-arm polyethylene glycol, and the aldehyde group in the iodinated multialdehyde compound is (0.3-5):(0.1-0.8):
1.
2. The CT imaging hydrogel according to claim 1, characterized in that The iodine-containing contrast agent is any one or more of iopromide, iopamidol, meglumine diatrizoate, iohexol or iodixanol.
3. The CT imaging hydrogel according to claim 1, characterized in that The iodinated polyaldehyde compound is iodine hexaldehyde.
4. The CT imaging hydrogel according to claim 1, characterized in that The number of arms of the succinimide ester-terminated multi-arm polyethylene glycol is selected from an integer of 4 to 10, and the molecular weight is 5000 to 20000.
5. A method for preparing a CT imaging hydrogel according to any one of claims 1 to 4, characterized in that: The following steps are involved: S1: mixing succinimide ester-terminated multi-arm polyethylene glycol, an iodinated multialdehyde compound and a first buffer solution to obtain solution A; mixing polylysine with a second buffer solution to obtain solution B; S2: Solution A and solution B are mixed to obtain a CT-developable hydrogel.
6. The preparation method according to claim 5, characterized in that The first buffer solution is PBS buffer, and the second buffer solution is borate buffer.
7. The preparation method according to claim 5, characterized in that The pH of the solution A is 6-7.5, and the pH of the solution B is 7-10.
8. A medical radiotherapy protective gasket, characterized in that: The invention comprises the CT imaging hydrogel according to any one of claims 1 to 4 or the CT imaging hydrogel prepared by the preparation method according to any one of claims 5 to 7.
Citation Information
Patent Citations
Medical hydrogel
CN109939065A
Developable hydrogel and preparation method thereof
CN114891242A
Iodine labeled hydrogels and precursors thereof with improved radiopacity
US20230127824A1
